Depression Treatment

The management of major depressive disorder requires a complex, structured, and personalized therapeutic approach, which considers the severity of symptoms, the patient’s clinical history, the presence of psychiatric or somatic comorbidities, and the response to previous treatments. The primary goal is not merely symptom reduction but the achievement of complete and sustained remission, with full recovery of psychosocial functioning and relapse prevention.

Treatment is based on two fundamental pillars: pharmacotherapy and psychotherapy. In cases of mild depression, a psychotherapeutic approach alone may be sufficient. However, in moderate to severe forms, or in recurrent presentations, a combination of both modalities is generally recommended. Integrating pharmacological and psychological interventions provides superior outcomes compared to either treatment alone, particularly in preventing relapse and addressing vulnerability factors.

The therapeutic strategy must be adapted to the phase of the disorder, with a differentiated approach during:

• Acute phase: aims at symptom reduction and functional recovery;
• Continuation phase: aims to consolidate remission and prevent relapse in the following months;
• Maintenance phase: in cases at high risk of recurrence, treatment should continue for at least 12 months, or longer in recurrent depressive disorders.

Pharmacotherapy

Antidepressant medications primarily act through modulation of central monoaminergic systems, especially serotonin, norepinephrine, and dopamine. Clinical response is not immediate: a symptomatic improvement generally requires 2–4 weeks, and treatment should be continued for at least 6–12 months after remission to prevent relapses.

The choice of antidepressant must be guided by a careful assessment considering:

• Symptom profile (apathy, insomnia, anxiety, agitation, suicidal ideation);
• Response to previous treatments;
• Somatic comorbidities and risk of drug interactions;
• Patient preferences and individual tolerability.

The main pharmacological classes used in depression treatment include:

• Tricyclic antidepressants (TCAs): effective but associated with significant side effects (anticholinergic, cardiovascular);
• Monoamine oxidase inhibitors (MAOIs): less frequently used due to safety concerns but useful in treatment-resistant cases;
• Second-generation antidepressants: include SSRIs, SNRIs, NaSSAs, and NDRIs, characterized by better tolerability and wide clinical use;
• Lithium salts: indicated in bipolar forms and patients at high suicide risk;
• Antidepressant-acting antipsychotics: used in combination for resistant episodes or those with psychotic features.

Therapeutic adherence is crucial: patients must be informed about the expected response timeline, possible side effects, and the importance of not discontinuing treatment prematurely. In the absence of a response after an adequate therapeutic trial, the following strategies may be considered:

• Dosage adjustment;
• Switch to another antidepressant;
• Pharmacological augmentation;
• Combination of different antidepressants.

Psychotherapy

Psychotherapy is a crucial component in the management of depression, serving as a primary treatment in mild cases and as an adjunct to pharmacotherapy in moderate to severe forms. Scientific evidence shows that the integration of psychological approaches enhances the overall effectiveness of treatment, helps address individual vulnerability factors, and reduces the risk of relapse.

Psychotherapeutic treatment generally unfolds in three phases:

• Acute phase (6–8 weeks): symptom reduction and establishment of a therapeutic alliance;
• Continuation phase (6–12 weeks): consolidation of remission and relapse prevention;
• Maintenance phase: variable duration, aimed at preventing recurrence in patients with recurrent depression.

The main evidence-based psychotherapeutic approaches for depression include:

• Behavioral therapy (BT): focuses on modifying dysfunctional behaviors through reinforcement strategies and engagement in rewarding activities;
• Cognitive or cognitive-behavioral therapy (CBT): aims to identify and modify negative, distorted cognitive patterns underlying depressive experience;
• Interpersonal therapy (IPT): targets relational problems, role transitions, and significant losses;
• Brief psychodynamic therapy (BPT): explores unconscious conflicts and deep affective dynamics related to depressive symptoms.

Psychotherapy effectiveness also depends on the patient’s motivation and awareness. It is essential to clearly communicate that depression is a treatable condition and that effective treatment requires commitment, continuity, and active collaboration. In some cases—particularly when the patient refuses pharmacological treatment or presents contraindications—psychotherapy may serve as the first-line intervention.

Intensive biological treatments

In cases of severe depression, especially when accompanied by psychotic or catatonic symptoms or an imminent risk of suicide, electroconvulsive therapy (ECT) may be indicated. Although historically stigmatized, modern ECT is a safe procedure performed under general anesthesia, with high efficacy and rapid action in severe and treatment-resistant cases.

In recent years, techniques based on neuromodulation have emerged, aimed at directly modulating dysfunctional neural activity. These include:

• Repetitive transcranial magnetic stimulation (rTMS): approved for treatment-resistant depression, this technique targets the left dorsolateral prefrontal cortex using focused electromagnetic pulses and does not require anesthesia;
• Deep brain stimulation (DBS): indicated in selected cases within experimental protocols, involving the implantation of electrodes in deep brain regions (e.g., subgenual area);
• Transcranial direct current stimulation (tDCS): an emerging technique that uses low-voltage electrical currents to modulate cortical excitability, still under clinical validation.

Emerging biological therapies

Several innovative compounds have shown efficacy in treatment-resistant depression:

• Ketamine and esketamine: ketamine, an NMDA receptor antagonist, exerts rapid antidepressant effects likely mediated by mechanisms of neuroplasticity. Esketamine is approved in intranasal form for controlled clinical use;
• Psychedelics: substances such as psilocybin and ayahuasca are under investigation for their ability to induce profound cognitive restructuring, with psychotherapeutic support;
• Pharmacogenetics: targeted genetic testing may guide the choice of antidepressant based on enzymatic profiles (e.g., CYP450), enhancing efficacy and minimizing adverse effects.

Integrative therapies

In addition to conventional treatments, a growing body of evidence supports the use of integrative strategies that can enhance treatment response and improve patient quality of life. These interventions, while not replacing primary therapies, may serve as effective complementary tools.

• Lifestyle interventions: regular physical activity, a balanced diet (e.g., Mediterranean diet), regulation of sleep-wake rhythms, and reduction in alcohol and psychotropic substance use significantly contribute to mood improvement;
• Mindfulness and meditation: mindfulness-based techniques (Mindfulness-Based Cognitive Therapy, MBCT) are effective in relapse prevention and in modulating stress and emotional reactivity;
• Nutraceutical interventions: substances such as omega-3, SAMe, vitamin D, tryptophan, and folate are being studied as adjuncts, with modest but potentially beneficial effects in selected contexts;
• Music therapy and pet therapy: techniques based on sensory and relational experience, used to enhance motivation, affectivity, and social engagement;
• Vagus nerve stimulation: a neuromodulation therapy involving implantation of a device that stimulates the vagus nerve, indicated in treatment-resistant forms.

All these strategies must be evaluated within the context of a comprehensive, multidisciplinary care plan. The introduction of integrative therapies should be discussed with the patient, based on available evidence, individual clinical profile, and resource availability.

This page provides a summary of the main therapeutic options currently available for the treatment of depression. Each modality will be further explored in dedicated sections, with detailed analysis of clinical indications, efficacy, contraindications, and strategies for therapeutic personalization. The optimal approach remains patient-centered, dynamic, and based on the best available scientific evidence.

Bibliography
1. Gelenberg AJ et al. Practice guideline for the treatment of patients with major depressive disorder. Am J Psychiatry. 2010;167(10 Suppl):1-152.
2. Cleare A et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459-525.
3. Cuijpers P et al. Psychotherapy for depression in adults: A meta-analysis of comparative outcome studies. J Consult Clin Psychol. 2008;76(6):909-922.
4. Rush AJ et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
5. Fava M et al. Augmentation and combination strategies in major depressive disorder. J Clin Psychiatry. 2009;70 Suppl 6:10-17.
6. APA. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). American Psychiatric Association, 2013.
7. Kennedy SH et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Can J Psychiatry. 2016;61(9):540-560.
8. Berlim MT et al. Repetitive transcranial magnetic stimulation for treating depression: A systematic review and meta-analysis of response, remission and dropout rates. Psychol Med. 2014;44(2):225-239.
9. Sanacora G et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74(4):399-405.
10. Carhart-Harris RL et al. Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology (Berl). 2018;235(2):399-408.
11. Cipriani A et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366.
12. Bschor T et al. Electroconvulsive therapy in depression – a review of the evidence. Dialogues Clin Neurosci. 2019;21(3):245-257.